Iterum Therapeutics PLC

NASDAQ ITRM

Download Data

Iterum Therapeutics PLC Accounts Payable Turnover Ratio 5 year CAGR for the quarter ending March 31, 2024: -100.00%

Iterum Therapeutics PLC Accounts Payable Turnover Ratio 5 year CAGR is -100.00% for the quarter ending March 31, 2024, a 0.00% change year over year. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Iterum Therapeutics PLC Accounts Payable Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Iterum Therapeutics PLC Accounts Payable Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Iterum Therapeutics PLC Accounts Payable Turnover Ratio for the quarter ending March 31, 2021 was 0.00, a 0.00% change year over year.
  • Iterum Therapeutics PLC Accounts Payable Turnover Ratio for the quarter ending March 31, 2020 was 0.00, a -100.00% change year over year.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email